1. Introducing JAK Inhibitors in Rheumatoid Arthritis

3. Introduction/Overview

4. The Human Canonical Model of JAK-STAT Signaling

5. The Biological Significance of Signaling Through Different JAK Combinations

6. Stratifying Non- or Inadequate- Treatment Response in RA

7. Tofacitinib JAK 1/3 Inhibitor: Clinical Trials in RA

8. Tofacitinib or ADA vs PBO in RA: Results From ORAL Standard

9. ACR 20 Responses Tofacitinib vs PBO: ORAL Solo

10. ACR 70 Responses Tofacitinib vs MTX: ORAL Start

11. ACR 20 Responses Tofacitinib vs PBO: ORAL Step

12. ACR 50 Responses Tofacitinib vs Tofacitinib + MTX and Adalimumab + MTX: ORAL Strategy

13. Baricitinib: Key Studies in RA Phase 3 Program and Their Characteristics

14. RA-BEAM Phase 3: ACR Outcomes at Weeks 12 and 24

15. RA-BEACON: Baricitinib in RA Patients With an Inadequate Response to TNF-ɑ Inhibitors

16. DARWIN 1 Phase 2: ACR Outcomes at Week 12 in MTX-IR: Filgotinib + MTX in Patients With Active RA

17. Other JAK Inhibitors in Development

18. JAK Inhibitors: Clinical Characteristics

19. Clinical Experience with JAK Inhibitors: Dr Fleischmann

20. ORAL Start: Patient-Reported Outcomes: Tofacitinib vs MTX

21. RA-BUILD Phase 3: PROs at Week 24 Baricitinib in csDMARD-IR and bDMARD-Naive Patients With Moderate to Severe RA

22. JAK Inhibitors: Safety Considerations

23. Summary and Conclusions

24. Abbreviations

25. Abbreviations (cont)

26. Abbreviations (cont)